Search

Your search keyword '"Niemann, Carsten Utoft"' showing total 459 results
Start Over Author "Niemann, Carsten Utoft"
459 results on '"Niemann, Carsten Utoft"'

4. Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study

Author

Al-Sawaf, Othman, Robrecht, Sandra, Zhang, Can, Olivieri, Stefano, Chang, Yi Meng, Fink, Anna Maria, Tausch, Eugen, Schneider, Christof, Ritgen, Matthias, Kreuzer, Karl-Anton, Sivchev, Liliya, Niemann, Carsten Utoft, Schwarer, Anthony, Loscertales, Javier, Weinkove, Robert, Strumberg, Dirk, Kilfoyle, Allanah, Manzoor, Beenish S., Jawaid, Dureshahwar, Emechebe, Nnadozie, Devine, Jacob, Boyer, Michelle, Runkel, Eva D., Eichhorst, Barbara, Stilgenbauer, Stephan, Jiang, Yanwen, Hallek, Michael, and Fischer, Kirsten

Published
2024
Full Text
View/download PDF

5. Deep immune cell phenotyping and induced immune cell responses at admission stratified by BMI in patients hospitalized with COVID-19: An observational multicenter cohort pilot study

Author

Sejdic, Adin, Hartling, Hans Jakob, Gitz Holler, Jon, Klingen Gjærde, Lars, Matovu Dungu, Arnold, Engel Møller, Maria Elizabeth, Svanberg Teglgaard, Rebecca, Utoft Niemann, Carsten Utoft, Brooks, Patrick Terrence, Mogensen, Trine H., Weis, Nina, Podlekareva, Daria, Baum Jørgensen, Marie Louise, Ortved Gang, Anne, Stampe Hersby, Ditte, Hald, Annemette, Dam Nielsen, Susanne, Lebech, Anne-Mette, Helleberg, Marie, Lundgren, Jens, Træholt Franck, Kristina, Fischer, Thea K., Barrella Harboe, Zitta, Marquart, Hanne Vibeke, Rye Ostrowski, Sisse, and Lindegaard, Birgitte

Published
2024
Full Text
View/download PDF

6. Reassessing the chronic lymphocytic leukemia International Prognostic Index in the era of targeted therapies

Author

Langerbeins, Petra, Giza, Adam, Robrecht, Sandra, Cramer, Paula, von Tresckow, Julia, Al-Sawaf, Othman, Fink, Anna Maria, Fürstenau, Moritz, Kutsch, Nadine, Simon, Florian, Goede, Valentin, Hoechstetter, Manuela, Niemann, Carsten Utoft, da Cunha-Bang, Caspar, Kater, Arnon, Dubois, Julie, Gregor, Michael, Staber, Philipp Bernhard, Tausch, Eugen, Schneider, Christof, Stilgenbauer, Stephan, Eichhorst, Barbara, Fischer, Kirsten, and Hallek, Michael

Published
2024
Full Text
View/download PDF

7. Author Correction: Early stimulated immune responses predict clinical disease severity in hospitalized COVID-19 patients

Author

Svanberg, Rebecka, MacPherson, Cameron, Zucco, Adrian, Agius, Rudi, Faitova, Tereza, Andersen, Michael Asger, da Cunha-Bang, Caspar, Gjærde, Lars Klingen, Møller, Maria Elizabeth Engel, Brooks, Patrick Terrence, Lindegaard, Birgitte, Sejdic, Adin, Harboe, Zitta Barrella, Gang, Anne Ortved, Hersby, Ditte Stampe, Brieghel, Christian, Nielsen, Susanne Dam, Podlekareva, Daria, Hald, Annemette, Bay, Jakob Thaning, Marquart, Hanne, Lundgren, Jens, Lebech, Anne-Mette, Helleberg, Marie, Niemann, Carsten Utoft, and Ostrowski, Sisse Rye

Published
2023
Full Text
View/download PDF

8. Risk of haematologic cancers among individuals tested for Borrelia burgdorferi antibodies, and Borrelia burgdorferi seropositive individuals: a nationwide population-based matched cohort study

Author

Tetens, Malte M., Omland, Lars Haukali, Dessau, Ram, Ellermann-Eriksen, Svend, Andersen, Nanna S., Jørgensen, Charlotte Sværke, Østergaard, Christian, Bodilsen, Jacob, Søgaard, Kirstine K., Bangsborg, Jette, Nielsen, Alex Christian, Møller, Jens Kjølseth, Chen, Ming, Niemann, Carsten Utoft, Lebech, Anne-Mette, and Obel, Niels

Published
2024
Full Text
View/download PDF

14. Immune cell populations and induced immune responses at admission in patients hospitalized with vaccine breakthrough SARS-CoV-2 infections

Author

Sejdic, Adin, primary, Hartling, Hans Jakob, additional, Holler, Jon Gitz, additional, Klingen Gjærde, Lars, additional, Lindegaard, Birgitte, additional, Dungu, Arnold Matovu, additional, Gnesin, Filip, additional, Møller, Maria Elizabeth Engel, additional, Teglgaard, Rebecca Svanberg, additional, Niemann, Carsten Utoft, additional, Brooks, Patrick Terrence, additional, Jørgensen, Charlotte Sværke, additional, Franck, Kristina Træholt, additional, Fischer, Thea K., additional, Marquart, Hanne Vibeke, additional, Harboe, Zitta Barrella, additional, and Ostrowski, Sisse Rye, additional

Published
2024
Full Text
View/download PDF

16. Early stimulated immune responses predict clinical disease severity in hospitalized COVID-19 patients

Author

Svanberg, Rebecka, MacPherson, Cameron, Zucco, Adrian, Agius, Rudi, Faitova, Tereza, Andersen, Michael Asger, da Cunha-Bang, Caspar, Gjærde, Lars Klingen, Møller, Maria Elizabeth Engel, Brooks, Patrick Terrence, Lindegaard, Birgitte, Sejdic, Adin, Gang, Anne Ortved, Hersby, Ditte Stampe, Brieghel, Christian, Nielsen, Susanne Dam, Podlekareva, Daria, Hald, Annemette, Bay, Jakob Thaning, Marquart, Hanne, Lundgren, Jens, Lebech, Anne-Mette, Helleberg, Marie, Niemann, Carsten Utoft, and Ostrowski, Sisse Rye

Published
2022
Full Text
View/download PDF

18. Complex Relationships between Diagnostics and Survival in Chronic Lymphocytic Leukemia in Denmark, Finland, Norway, and Sweden.

Author

Hemminki, Kari, Zitricky, Frantisek, Försti, Asta, Tapaninen, Tuija, Hemminki, Akseli, Juliusson, Gunnar, and Niemann, Carsten Utoft

Subjects
CHRONIC lymphocytic leukemia diagnosis, CHRONIC lymphocytic leukemia, MORTALITY, RESEARCH funding, SEX distribution, AGE distribution, DESCRIPTIVE statistics, CHRONIC diseases
Abstract

Simple Summary: Chronic lymphocytic leukemia (CLL) is a common leukemia characterized by an accumulation of lymphocytes in the blood and lymphoid organs. Disease presentation is highly variable as many patients do not initially require any treatment, and a watch and wait strategy remains the standard of care for up to 50% of patients. However, for those with a progressive disease, chemotherapy is the standard treatment and has improved over the years, increasing the survival of patients. We analyze here age-specific relative survival trends in CLL through 50 years up to 2020s in Denmark, Finland, Norway, and Sweden using the NORDCAN database. The large age-specific survival differences in 1972–76 almost disappeared by 2017–21. While 5-year survival in younger patients exceeded 90%, for those diagnosed at age 80–89-years, survival improved later, reaching 90% in Denmark and less in the other countries. Survival in Denmark is probably among the best in the world, which could be achieved by boosting survival even among the oldest patients. Most Nordic survival rates were better than those in the USA. Background: Chronic lymphocytic leukemia (CLL) is a common hematological malignancy with highly variable clinical presentation. Many patients never require any treatment but for the others, chemotherapy, immunochemotherapy, and newer targeted therapies have changed the treatment landscape. Diagnostic age influences the applied treatment, and we thus wanted to analyze age-specific survival trends through 50 years up to 2020s. Methods: We used 1- and 5-year relative survival from the NORDCAN database, with data from Denmark (DK), Finland (FI), Norway (NO), and Sweden (SE). Because of the variable presentation of CLL, we also considered incidence and mortality trends. For comparison, US SEER data were used. Results: The large age-specific survival differences in 1972–76 almost disappeared by 2017–21. While 5-year survival in younger patients exceeded 90%, for those diagnosed at age 80–89 years, survival reached 90% in DK and SE women, 80% in NO and SE men, but only 50% in FI. DK 5-year overall survival for men was 92.4%, and for women, it was 96.3%. These survival figures were higher than age-group-specific US survival data. Conclusions: The DK data are probably global top figures for national survival which could be achieved by boosting survival even among the oldest patients. The qualification to these figures and international comparisons is that survival needs to be considered in terms of incidence, which is high in DK and NO. Low survival of the FI 80–89-year-old patients, even in the first year after diagnosis, may suggest delayed diagnosis, which should call for a closer national scrutiny. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

20. The Danish Lymphoid Cancer Research (DALY-CARE) data resource: the basis for developing data-driven hematology

Author

Brieghel, Christian, primary, Werling, Mikkel, additional, Frederiksen, Casper Moller, additional, Parviz, Mehdi, additional, da Cunha-Bang, Caspar, additional, Faitova, Tereza, additional, Teglgaard, Rebecca Svanberg, additional, Vainer, Noomi, additional, Lacoppidan, Thomas, additional, Rotbain, Emelie, additional, Agius, Rudi, additional, and Niemann, Carsten Utoft, additional

Published
2024
Full Text
View/download PDF

23. Clonal hematopoiesis and COVID-19 hospitalization in Danish adults

Author

Burgos Sequeros, Celia, Tulstrup, Morten, Bliddal, Sofie, Sørensen, Karina Meden, Nissen, Ioanna, Rezahosseini, Omid, Brooks, Patrick Terrence, Feenstra, Bjarke, Gang, Anne Ortved, Geller, Frank, Hald, Annemette, Harboe, Zitta Barrella, Helleberg, Marie, Jespersen, Jakob S., Lebech, Anne Mette, Lindegaard, Birgitte, Mogensen, Trine H., Møller, Maria Elizabeth Engel, Nielsen, Claus Henrik, Niemann, Carsten Utoft, Podlekareva, Daria, Sejdic, Adin, Sørensen, Erik, Teglgaard, Rebecca Svanberg, Tommerup, Niels, Weis, Nina, Brunak, Søren, Pedersen, Ole Birger Vestager, Banasik, Karina, Feldt-Rasmussen, Ulla, Nielsen, Susanne Dam, Ostrowski, Sisse Rye, Grønbæk, Kirsten, Burgos Sequeros, Celia, Tulstrup, Morten, Bliddal, Sofie, Sørensen, Karina Meden, Nissen, Ioanna, Rezahosseini, Omid, Brooks, Patrick Terrence, Feenstra, Bjarke, Gang, Anne Ortved, Geller, Frank, Hald, Annemette, Harboe, Zitta Barrella, Helleberg, Marie, Jespersen, Jakob S., Lebech, Anne Mette, Lindegaard, Birgitte, Mogensen, Trine H., Møller, Maria Elizabeth Engel, Nielsen, Claus Henrik, Niemann, Carsten Utoft, Podlekareva, Daria, Sejdic, Adin, Sørensen, Erik, Teglgaard, Rebecca Svanberg, Tommerup, Niels, Weis, Nina, Brunak, Søren, Pedersen, Ole Birger Vestager, Banasik, Karina, Feldt-Rasmussen, Ulla, Nielsen, Susanne Dam, Ostrowski, Sisse Rye, and Grønbæk, Kirsten

Published
2024

24. Risk of haematologic cancers among individuals tested for Borrelia burgdorferi antibodies, and Borrelia burgdorferi seropositive individuals:a nationwide population-based matched cohort study

Author

Tetens, Malte M., Omland, Lars Haukali, Dessau, Ram, Ellermann-Eriksen, Svend, Andersen, Nanna S., Jørgensen, Charlotte Sværke, Østergaard, Christian, Bodilsen, Jacob, Søgaard, Kirstine K., Bangsborg, Jette, Nielsen, Alex Christian, Møller, Jens Kjølseth, Chen, Ming, Niemann, Carsten Utoft, Lebech, Anne Mette, Obel, Niels, Tetens, Malte M., Omland, Lars Haukali, Dessau, Ram, Ellermann-Eriksen, Svend, Andersen, Nanna S., Jørgensen, Charlotte Sværke, Østergaard, Christian, Bodilsen, Jacob, Søgaard, Kirstine K., Bangsborg, Jette, Nielsen, Alex Christian, Møller, Jens Kjølseth, Chen, Ming, Niemann, Carsten Utoft, Lebech, Anne Mette, and Obel, Niels

Abstract

Objectives In a nationwide, matched cohort study, we aimed to investigate risks of haematologic cancers among individuals tested for Borrelia burgdorferi (Bb) antibodies, and among serum Bb seropositive individuals. Methods We identified all Bb seropositive individuals in Denmark (1993–2020) (n = 52 200) and constructed two age- and sex-matched comparison cohorts: (a) Bb seronegative controls (n = 104 400) and (b) background population controls (n = 261 000). We calculated short-term OR (aOR) (<1 month of study inclusion), and long-term hazard ratios (aHR) (>1 month after study inclusion) adjusted for age and sex. We stratified seropositive individuals on only Bb-IgM seropositive (n = 26 103), only Bb-IgG seropositive (n = 18 698), and Bb-IgM-and-IgG seropositive (n = 7399). Results Compared with the background population, individuals tested for Bb antibodies had increased short-term (aOR: 12.6, 95% CI: 10.1–15.6) and long-term (aHR: 1.3, 95% CI: 1.2–1.4) risk of haematologic cancers. The Bb seropositive individuals had no increased risk of haematologic cancers compared with those who tested negative for Bb, except that Bb-IgM-and-IgG seropositive individuals had increased long-term risk of chronic lymphatic leukaemia (aHR: 2.0, 95% CI: 1.2–3.4). Discussion Our results suggest that Bb antibody testing is included in the work-up of unspecific symptoms preceding diagnosis of haematologic cancers. Bb-IgM-and-IgG seropositivity was associated with a two-fold increased long-term risk of chronic lymphatic leukaemia, which warrants further investigation., Objectives: In a nationwide, matched cohort study, we aimed to investigate risks of haematologic cancers among individuals tested for Borrelia burgdorferi (Bb) antibodies, and among serum Bb seropositive individuals. Methods: We identified all Bb seropositive individuals in Denmark (1993–2020) (n = 52 200) and constructed two age- and sex-matched comparison cohorts: (a) Bb seronegative controls (n = 104 400) and (b) background population controls (n = 261 000). We calculated short-term OR (aOR) (<1 month of study inclusion), and long-term hazard ratios (aHR) (>1 month after study inclusion) adjusted for age and sex. We stratified seropositive individuals on only Bb-IgM seropositive (n = 26 103), only Bb-IgG seropositive (n = 18 698), and Bb-IgM-and-IgG seropositive (n = 7399). Results: Compared with the background population, individuals tested for Bb antibodies had increased short-term (aOR: 12.6, 95% CI: 10.1–15.6) and long-term (aHR: 1.3, 95% CI: 1.2–1.4) risk of haematologic cancers. The Bb seropositive individuals had no increased risk of haematologic cancers compared with those who tested negative for Bb, except that Bb-IgM-and-IgG seropositive individuals had increased long-term risk of chronic lymphatic leukaemia (aHR: 2.0, 95% CI: 1.2–3.4). Discussion: Our results suggest that Bb antibody testing is included in the work-up of unspecific symptoms preceding diagnosis of haematologic cancers. Bb-IgM-and-IgG seropositivity was associated with a two-fold increased long-term risk of chronic lymphatic leukaemia, which warrants further investigation.

Published
2024

25. Immune Dysfunction and Infection - Interaction between CLL and Treatment:A Reflection on Current Treatment Paradigms and Unmet Needs

Author

Gargiulo, Ernesto, Teglgaard, Rebecca Svanberg, Faitová, Tereza, Niemann, Carsten Utoft, Gargiulo, Ernesto, Teglgaard, Rebecca Svanberg, Faitová, Tereza, and Niemann, Carsten Utoft

Abstract

Background: Chronic lymphocytic leukemia (CLL) is a hematological malignancy characterized by immune dysfunction, which significantly contributes to increased morbidity and mortality due to infections. Summary: Advancement in therapeutic strategies based on combination chemoimmunotherapy and targeted treatment have increased life expectancy for patients affected by CLL. However, mortality and morbidity due to infection showed no improvement over the last decades. Although therapy options are highly efficient in targeting leukemic cells, several studies highlighted the interactions of different treatments with the tumor microenvironment immune components, significantly impacting their clinical efficacy and fostering increased risk of infections. Key Messages: Given the profound immune dysfunction caused by CLL itself, treatment can thus represent a double-edged sword. Thus, it is essential to increase our understanding and awareness on how conventional therapies affect the disease-microenvironment-infection axis to ensure the best personalized strategy for each patient. This requires careful consideration of the advantages and disadvantages of efficient treatments, whether chemoimmunotherapy or targeted combinations, leading to risk of infectious complications. To this regard, our machine learning-based algorithm CLL Treatment-Infection Model, currently implemented into the local electronic health record system for Eastern Denmark, aims at early identification of patients at high risk of serious infections (PreVent-ACaLL; NCT03868722). We here review strategies for management of immune dysfunction and infections in CLL., BACKGROUND: Chronic lymphocytic leukemia (CLL) is a hematological malignancy characterized by immune dysfunction, which significantly contributes to increased morbidity and mortality due to infections. SUMMARY: Advancement in therapeutic strategies based on combination chemoimmunotherapy and targeted treatment have increased life expectancy for patients affected by CLL. However, mortality and morbidity due to infection showed no improvement over the last decades. Although therapy options are highly efficient in targeting leukemic cells, several studies highlighted the interactions of different treatments with the tumor microenvironment immune components, significantly impacting their clinical efficacy and fostering increased risk of infections. KEY MESSAGES: Given the profound immune dysfunction caused by CLL itself, treatment can thus represent a double-edged sword. Thus, it is essential to increase our understanding and awareness on how conventional therapies affect the disease-microenvironment-infection axis to ensure the best personalized strategy for each patient. This requires careful consideration of the advantages and disadvantages of efficient treatments, whether chemoimmunotherapy or targeted combinations, leading to risk of infectious complications. To this regard, our machine learning-based algorithm CLL Treatment-Infection Model, currently implemented into the local electronic health record system for Eastern Denmark, aims at early identification of patients at high risk of serious infections (PreVent-ACaLL; NCT03868722). We here review strategies for management of immune dysfunction and infections in CLL.

Published
2024

27. Infections in patients with chronic lymphocytic leukemia treated with time limited targeted drug combinations.

Author

Langerbeins, Petra, Giza, Adam, Robrecht, Sandra, Cramer, Paula, von Tresckow, Julia, Al‐Sawaf, Othman, Fink, Anna Maria, Fürstenau, Moritz, Kater, Arnon P., van der Spek, Ellen, Niemann, Carsten Utoft, da Cunha‐Bang, Caspar, Tausch, Eugen, Schneider, Christof, Stilgenbauer, Stephan, Fischer, Kirsten, Hallek, Michael, and Eichhorst, Barbara

Published
2024
Full Text
View/download PDF

28. Clonal hematopoiesis and COVID‐19 hospitalization in Danish adults.

Author

Sequeros, Celia Burgos, Tulstrup, Morten, Bliddal, Sofie, Sørensen, Karina Meden, Nissen, Ioanna, Rezahosseini, Omid, Brooks, Patrick Terrence, Feenstra, Bjarke, Gang, Anne Ortved, Geller, Frank, Hald, Annemette, Harboe, Zitta Barrella, Helleberg, Marie, Jespersen, Jakob S., Lebech, Anne‐Mette, Lindegaard, Birgitte, Mogensen, Trine H., Møller, Maria Elizabeth Engel, Nielsen, Claus Henrik, and Niemann, Carsten Utoft

Published
2024
Full Text
View/download PDF

29. Risk of haematologic cancers among individuals tested for Borrelia burgdorferi antibodies, and Borrelia burgdorferi seropositive individuals: a nationwide population-based matched cohort study

Author

Tetens, Malte M., primary, Omland, Lars Haukali, additional, Dessau, Ram, additional, Ellermann-Eriksen, Svend, additional, Andersen, Nanna S., additional, Jørgensen, Charlotte Sværke, additional, Østergaard, Christian, additional, Bodilsen, Jacob, additional, Søgaard, Kirstine K., additional, Bangsborg, Jette, additional, Nielsen, Alex Christian, additional, Møller, Jens Kjølseth, additional, Chen, Ming, additional, Niemann, Carsten Utoft, additional, Lebech, Anne-Mette, additional, and Obel, Niels, additional

Published
2023
Full Text
View/download PDF

33. Immune Dysfunction and Infection – Interaction between CLL and Treatment: A Reflection on Current Treatment Paradigms and Unmet Needs.

Author

Gargiulo, Ernesto, Teglgaard, Rebecca Svanberg, Faitová, Tereza, and Niemann, Carsten Utoft

Abstract

Background: Chronic lymphocytic leukemia (CLL) is a hematological malignancy characterized by immune dysfunction, which significantly contributes to increased morbidity and mortality due to infections. Summary: Advancement in therapeutic strategies based on combination chemoimmunotherapy and targeted treatment have increased life expectancy for patients affected by CLL. However, mortality and morbidity due to infection showed no improvement over the last decades. Although therapy options are highly efficient in targeting leukemic cells, several studies highlighted the interactions of different treatments with the tumor microenvironment immune components, significantly impacting their clinical efficacy and fostering increased risk of infections. Key Messages: Given the profound immune dysfunction caused by CLL itself, treatment can thus represent a double-edged sword. Thus, it is essential to increase our understanding and awareness on how conventional therapies affect the disease-microenvironment-infection axis to ensure the best personalized strategy for each patient. This requires careful consideration of the advantages and disadvantages of efficient treatments, whether chemoimmunotherapy or targeted combinations, leading to risk of infectious complications. To this regard, our machine learning-based algorithm CLL Treatment-Infection Model, currently implemented into the local electronic health record system for Eastern Denmark, aims at early identification of patients at high risk of serious infections (PreVent-ACaLL; NCT03868722). We here review strategies for management of immune dysfunction and infections in CLL. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

35. Impact of type 2 diabetes on mortality, cause of death, and treatment in chronic lymphocytic leukemia

Author

Rotbain, Emelie Curovic, primary, Allmer, Cristine, additional, Rostgaard, Klaus, additional, Andersen, Michael Asger, additional, Vainer, Noomi, additional, da Cunha‐Bang, Caspar, additional, Parikh, Sameer A., additional, Rabe, Kari G., additional, Hjalgrim, Henrik, additional, Frederiksen, Henrik, additional, Slager, Susan L., additional, and Niemann, Carsten Utoft, additional

Published
2023
Full Text
View/download PDF

36. High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations

Author

Fürstenau, Moritz, primary, Thus, Yvonne J., additional, Robrecht, Sandra, additional, Mellink, Clemens H.M., additional, van der Kevie-Kersemaekers, Anne-Marie F., additional, Dubois, Julie, additional, von Tresckow, Julia, additional, Patz, Michaela, additional, Gregor, Michael, additional, Thornton, Patrick, additional, Staber, Philipp B., additional, Tadmor, Tamar, additional, Levin, Mark-David, additional, da Cunha-Bang, Caspar, additional, Schneider, Christof, additional, Poulsen, Christian Bjørn, additional, Illmer, Thomas, additional, Schöttker, Björn, additional, Janssens, Ann, additional, Christiansen, Ilse, additional, Noesslinger, Thomas, additional, Baumann, Michael, additional, Hebart, Holger, additional, Gaska, Tobias, additional, Regelink, Josien, additional, Dompeling, Ellen C., additional, Lindstrom, Vesa, additional, Juliusson, Gunnar, additional, Widmer, Anouk Andrea, additional, Goede, Jeroen S., additional, Goldschmidt, Neta, additional, Simon, Florian, additional, De Silva, Nisha, additional, Fink, Anna Maria, additional, Fischer, Kirsten, additional, Wendtner, Clemens-Martin, additional, Ritgen, Matthias, additional, Brüggemann, Monika, additional, Tausch, Eugen, additional, Spaargaren, Marcel, additional, Eldering, Eric, additional, Stilgenbauer, Stephan, additional, Niemann, Carsten Utoft, additional, Hallek, Michael, additional, Eichhorst, Barbara, additional, Kreuzer, Karl-Anton, additional, and Kater, Arnon P., additional

Published
2023
Full Text
View/download PDF

38. Spontaneous regression in chronic lymphocytic leukaemia. Clinical features of 50 cases from the ERIC registry and review of the literature

Author

Del Giudice, Ilaria, Cappelli, Luca Vincenzo, Delgado, Julio, Niemann, Carsten Utoft, Andersen, Michael Asger, Rotbain, Emelie Hamotal Curovic, Aarup, Kathrine, Walewska, Renata, Visentin, Andrea, Deodato, Marina, Frustaci, Anna Maria, Cavalloni, Chiara, Gentile, Massimo, Yassin, Mohamed A., Lad, Deepesh, Scarfo, Lydia, Flogegard, Max, Mattsson, Mattias, Raponi, Sara, Ilari, Caterina, Starza, Irene Della, Orlandi, Ester M., Tedeschi, Alessandra, Trentin, Livio, Semenzato, Gianpietro, Guarini, Anna, Ghia, Paolo, Montserrat, Emili, Foa, Robin, Del Giudice, Ilaria, Cappelli, Luca Vincenzo, Delgado, Julio, Niemann, Carsten Utoft, Andersen, Michael Asger, Rotbain, Emelie Hamotal Curovic, Aarup, Kathrine, Walewska, Renata, Visentin, Andrea, Deodato, Marina, Frustaci, Anna Maria, Cavalloni, Chiara, Gentile, Massimo, Yassin, Mohamed A., Lad, Deepesh, Scarfo, Lydia, Flogegard, Max, Mattsson, Mattias, Raponi, Sara, Ilari, Caterina, Starza, Irene Della, Orlandi, Ester M., Tedeschi, Alessandra, Trentin, Livio, Semenzato, Gianpietro, Guarini, Anna, Ghia, Paolo, Montserrat, Emili, and Foa, Robin

Published
2023
Full Text
View/download PDF

39. Impact of type 2 diabetes on mortality, cause of death, and treatment in chronic lymphocytic leukemia

Author

Rotbain, Emelie Curovic, Allmer, Cristine, Rostgaard, Klaus, Andersen, Michael Asger, Vainer, Noomi, da Cunha-Bang, Caspar, Parikh, Sameer A., Rabe, Kari G., Hjalgrim, Henrik, Frederiksen, Henrik, Slager, Susan L., Niemann, Carsten Utoft, Rotbain, Emelie Curovic, Allmer, Cristine, Rostgaard, Klaus, Andersen, Michael Asger, Vainer, Noomi, da Cunha-Bang, Caspar, Parikh, Sameer A., Rabe, Kari G., Hjalgrim, Henrik, Frederiksen, Henrik, Slager, Susan L., and Niemann, Carsten Utoft

Abstract

Age-related comorbid conditions are exceedingly common in patients with chronic lymphocytic leukemia (CLL). As the prevalence of type 2 diabetes (T2D) is predicted to double during the next two decades, a better understanding of the interplay between CLL and T2D is of increasing importance. In this study, analyses were performed in parallel in two separate cohorts, based on Danish national registers and the Mayo Clinic CLL Resource. The primary outcomes were overall survival (OS) from time of CLL diagnosis, OS from time of treatment, and time to first treatment (TTFT), studied using Cox proportional hazard regression analysis and Fine-Gray regression analysis. In the Danish CLL cohort, the prevalence of T2D was 11%, in the Mayo CLL cohort, it was 12%. Patients with CLL and T2D had shorter OS both from time of diagnosis and from first-line treatment for were less likely to receive treatment for CLL compared with patients with CLL and without T2D. The increased mortality was largely driven by an increased risk of death due to infections, especially in the Danish cohort. The findings of this study emphasize a substantial subgroup of CLL patients with co-occurring T2D with an inferior prognosis and a possible unmet treatment need requiring additional interventions and further research.

Published
2023

43. Spontaneous regression in chronic lymphocytic leukaemia. Clinical features of 50 cases from the ERIC registry and review of the literature

Author

Del Giudice, Ilaria, primary, Cappelli, Luca Vincenzo, additional, Delgado, Julio, additional, Niemann, Carsten Utoft, additional, Andersen, Michael Asger, additional, Rotbain, Emelie Hamotal Curovic, additional, Aarup, Kathrine, additional, Walewska, Renata, additional, Visentin, Andrea, additional, Deodato, Marina, additional, Frustaci, Anna Maria, additional, Cavalloni, Chiara, additional, Gentile, Massimo, additional, Yassin, Mohamed A., additional, Lad, Deepesh, additional, Scarfò, Lydia, additional, Flogegard, Max, additional, Mattsson, Mattias, additional, Raponi, Sara, additional, Ilari, Caterina, additional, Starza, Irene Della, additional, Orlandi, Ester M., additional, Tedeschi, Alessandra, additional, Trentin, Livio, additional, Semenzato, Gianpietro, additional, Guarini, Anna, additional, Ghia, Paolo, additional, Montserrat, Emili, additional, and Foà, Robin, additional

Published
2023
Full Text
View/download PDF

44. High Karyotypic Complexity and Translocations Are Adverse Prognostic Features in Patients with Chronic Lymphocytic Leukemia without TP53 Aberrations Treated with Venetoclax-Based Time-Limited Combinations

Author

Furstenau, Moritz, Thus, Yvonne, Robrecht, Sandra, Mellink, Clemens, der Kevie-Kersemaekers, Anne-Marie, Dubois, Julie M. N., Von Tresckow, Julia, Patz, Michaela, Gregor, Michael, Thornton, Patrick, Staber, Philipp B., Tadmor, Tamar, Levin, Mark-David, da Cunha-Bang, Caspar, Schneider, Christof, Poulsen, Christian Bjørn, Illmer, Thomas, Schöttker, Björn, Janssens, Ann, Christiansen, Ilse, Baumann, Michael, Noesslinger, Thomas, Regelink, Josien, Dompeling, Ellen C, Lindström, Vesa, Juliusson, Gunnar, Widmer, Anouk, Goede, Jeroen Simon, Goldschmidt, Neta, Simon, Florian, De Silva, Nisha, Fink, Anna-Maria, Fischer, Kirsten, Wendtner, Clemens-Martin, Ritgen, Matthias, Brüggemann, Monika, Tausch, Eugen, Stilgenbauer, Stephan, Eldering, Eric, Niemann, Carsten Utoft, Hallek, Michael, Eichhorst, Barbara, Kreuzer, Karl-Anton, and Kater, Arnon P.

Subjects
Immunology, Cell Biology, Hematology, Biochemistry
Published
2022

45. Anti-PD-L1/PD-L2 therapeutic vaccination in untreated chronic lymphocytic leukemia patients with unmutated IgHV

Author

Klausen, Uffe, primary, Grauslund, Jacob Handlos, additional, Jørgensen, Nicolai Grønne Dahlager, additional, Ahmad, Shamaila Munir, additional, Jonassen, Merete, additional, Weis-Banke, Stine Emilie, additional, Martinenaite, Evelina, additional, Pedersen, Lone Bredo, additional, Lisle, Thomas Landkildehus, additional, Gang, Anne Ortved, additional, Enggaard, Lisbeth, additional, Hansen, Morten, additional, Holmström, Morten Orebo, additional, Met, Özcan, additional, Svane, Inge Marie, additional, Niemann, Carsten Utoft, additional, Pedersen, Lars Møller, additional, and Andersen, Mads Hald, additional

Published
2022
Full Text
View/download PDF

48. Differences in Clinical Course and Management of Sars-CoV2 Infection in Patients with Chronic Lymphocytic Leukemia between the Sequential Pandemic Phases: An Eric Study

Author

Visentin, Andrea, primary, Scarfò, Lydia, additional, Chatzikonstantinou, Thomas, additional, Kapetanakis, Anargyros, additional, Demosthenous, Christos, additional, Karakatsoulis, Georgios, additional, Andres, Martin, additional, Antic, Darko, additional, Allsup, David, additional, Baile, Mónica, additional, Bron, Dominique, additional, Capasso, Antonella, additional, Catherwood, Mark, additional, Collado, Rosa, additional, Cordoba, Raul, additional, Cuéllar-García, Carolina, additional, Delgado, Julio, additional, Dimou, Maria, additional, Doubek, Michael, additional, De Paoli, Lorenzo, additional, De Paolis, Maria Rosaria, additional, Del Poeta, Giovanni, additional, Efstathopoulou, Maria, additional, Shimaa, El-Ashwah, additional, Enrico, Alicia, additional, Farina, Lucia, additional, Ferrari, Angela, additional, Foglietta, Myriam, additional, Furstenau, Moritz, additional, Garcia-Marco, Jose A., additional, Gentile, Massimo, additional, Gimeno, Eva, additional, Maria, Gomes da Silva, additional, Gutwein, Odit, additional, Hakobyan, Yervand, additional, Herishanu, Yair, additional, Hernandez, jose Angel, additional, Herold, Tobias, additional, Iyengar, Sunil, additional, Itchaki, Gilad, additional, Jaksic, Ozren, additional, Janssens, Ann, additional, Kalashnikova, Olga, additional, Kalicinska, Elzbieta, additional, Kater, Arnon P., additional, Kersting, Sabina, additional, Labrador, Jorge, additional, Lad, Deepesh, additional, Laurenti, Luca, additional, Levin, Mark-David, additional, Lista, Enrico, additional, Malerba, Lara, additional, Marasca, Roberto, additional, Marchetti, Monia, additional, Marquet Palomanes, Juan, additional, Mattsson, Mattias, additional, Mauro, Francesca Romana, additional, Mayor-Bastida, Carlota, additional, Morawska, Marta, additional, Motta, Marina, additional, Munir, Talha, additional, Murru, Roberta, additional, Milosevic, Ivana, additional, Miras Calvo, Fatima, additional, Niemann, Carsten Utoft, additional, Olivieri, Jacopo, additional, Orsucci, Lorella, additional, Papaioannou, Maria, additional, Pavlovsky, Miguel Arturo, additional, Piskunova, Inga S., additional, Pocali, Barbara, additional, Popov, Viola Maria, additional, Quaglia, Francesca Maria, additional, Quaresmini, Giulia, additional, Raa, Doreen te, additional, Reda, Gianluigi, additional, Rigolin, Gian Matteo, additional, Ruchlemer, Rosa, additional, Shrestha, Amit, additional, Šimkovič, Martin, additional, Špaček, Martin, additional, Sportoletti, Paolo, additional, Stanca Ciocan, Oana, additional, Tadmor, Tamar, additional, Vandenberghe, Elisabeth, additional, Varettoni, Marzia, additional, Vitale, Candida, additional, Van Der Spek, Ellen, additional, Van Gelder, Michel, additional, Wasik-Szczepanek, Ewa, additional, Yáñez, Lucrecia, additional, Yassin, Mohamed A, additional, Coscia, Marta, additional, Eichhorst, Barbara, additional, Rambaldi, Alessandro, additional, Stavroyianni, Niki, additional, Trentin, Livio, additional, Stamatopoulos, Kostas, additional, and Ghia, Paolo, additional

Published
2022
Full Text
View/download PDF

49. Venetoclax, Lenalidomide and Rituximab for Patients with Relapsed or Refractory Mantle Cell Lymphoma - the Nordic Lymphoma Group NLG-MCL7 (VALERIA) Phase Ib-II Trial

Author

Jerkeman, Mats, primary, Kolstad, Arne, additional, Hutchings, Martin, additional, Pasanen, Annika, additional, Meriranta, Leo, additional, Niemann, Carsten Utoft, additional, Rask Kragh Jørgensen, Rasmus, additional, El-Galaly, Tarec Christoffer Christoffer, additional, Riise, Jon, additional, Leppä, Sirpa, additional, Christensen, Jacob Haaber, additional, Wader, Karin Fahl, additional, and Glimelius, Ingrid, additional

Published
2022
Full Text
View/download PDF

50. Functional Anti-Apoptotic Protein Dependence and Its Relation to Genomic Prognostic Markers and Response to Treatment in Chronic Lymphocytic Leukemia

Author

Chong, Stephen Jun Fei, primary, Lu, Junyan, additional, Valentin, Rebecca, additional, Lehmberg, Timothy Z., additional, Collins, Mary C, additional, Herbaux, Charles, additional, Niemann, Carsten Utoft, additional, Huber, Wolfgang, additional, Zenz, Thorsten, additional, and Davids, Matthew S., additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results